What Makes Pulmonx Corporation (LUNG) a Strong Momentum Stock: Buy Now?
Pulmonx Corporation (LUNG) has been identified as a strong momentum stock by Zacks Equity Research, boasting a Momentum Style Score of B and a Zacks Rank of #2 (Buy). The company has shown significant short-term and long-term price performance, outperforming both its industry and the S&P 500. Positive earnings estimate revisions further contribute to its promising outlook for investors seeking near-term growth.
Morgan Stanley (LUNG) reports 6.9% Pulmonx stake in updated ownership filing
Morgan Stanley and Morgan Stanley Capital Services LLC have filed an amended Schedule 13G, disclosing their beneficial ownership in Pulmonx Corp (LUNG). Morgan Stanley reports a 6.9% stake, representing 2,920,241 shares, while Morgan Stanley Capital Services LLC reports a 6.8% stake, or 2,885,147 shares. All reported shares are held with shared voting and dispositive power.
Pulmonx (LUNG) Q2 2026 Earnings Call Transcript
Pulmonx (LUNG) reported its Q2 2026 earnings, highlighting a 34% reduction in net loss and a 39% decrease in adjusted EBITDA loss, driven by cost alignment initiatives. The company reiterated its full-year revenue guidance of $90 million to $92 million and expects to return to year-over-year sales growth later in 2026, partly due to the renewal of its Chinese registration certificate and stabilizing U.S. sales force. Pulmonx also emphasized the potential of its AeriSeal product to expand the total addressable market by approximately 20% globally, with CONVERT II trial enrollment on track for completion in 2027.
Pulmonx Corp 2026: Revenue $22.76M, EPS ($0.24) — 10-Q Summary
Pulmonx Corp reported its 2026 quarterly results, showing revenue of $22.76 million and a diluted EPS of ($0.24), an improvement from the prior year. The company experienced a decline in revenue due to lower procedure volumes, particularly in the U.S. and China, but saw an improved gross margin and continued commercial expansion efforts.
Pulmonx (LUNG) Upgraded to Buy: What Does It Mean for the Stock?
Pulmonx (LUNG) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates. The Zacks rating system highlights the strong correlation between changes in future earnings potential and near-term stock price movements, suggesting positive investor sentiment and potential for stock appreciation. This upgrade places Pulmonx in the top 20% of Zacks-covered stocks based on estimate revisions, indicating a strong candidate for market-beating returns.
Earnings Release: Here's Why Analysts Cut Their Pulmonx Corporation (NASDAQ:LUNG) Price Target To US$3.40
Pulmonx Corporation's Q2 results showed revenues in line with predictions and smaller-than-expected statutory losses. Despite the positive earnings surprise, analysts have lowered their average price target to US$3.40, indicating reduced optimism about the company's future valuation. While revenue growth is expected to slow, it is still projected to align with the industry average.
Lake Street Maintains Pulmonx(LUNG.US) With Buy Rating, Maintains Target Price $4
Lake Street has reiterated its Buy rating for Pulmonx (LUNG.US) and maintained its price target at $4. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Pulmonx Affirms FY26 Sales Guidance of $90.000M-$92.000M
Pulmonx (NASDAQ: LUNG) has reiterated its full-year 2026 sales guidance, keeping the range at $90.000 million to $92.000 million. This guidance is consistent with previous statements and aligns closely with the consensus analyst estimate of $90.832 million. The affirmation signals management's confidence in the company's operational performance and ability to meet financial targets for the fiscal year.
Pulmonx Corp Q2 revenue falls, but beats estimates
Pulmonx Corp's Q2 revenue experienced a decline but still managed to surpass analyst estimates. The article, sourced from Reuters via TradingView News, provides a brief update on the company's financial performance.
Pulmonx Corporation (LUNG) Reports Q2 Loss, Beats Revenue Estimates
Pulmonx Corporation (LUNG) reported a Q2 loss of $0.24 per share, surpassing the Zacks Consensus Estimate of a $0.28 loss, and also beat revenue expectations with $22.76 million. Despite underperforming the market year-to-date, the company has consistently topped revenue estimates in the past four quarters, and its stock currently holds a Zacks Rank #3 (Hold).
LUNG|Pulmonx Corp|Price:1.245|Chg%:-0.005
This article provides a detailed financial overview of Pulmonx Corp (LUNG), including its stock performance, key financial indicators, and historical data. It presents an all-in-one data dashboard for smart investors, organizing complex financial statements into customizable views. The report covers the income statement, balance sheet, and cash flow statement, highlighting the latest annual financial report and quarterly performance breakdowns.
BlackRock (LUNG) updates Pulmonx Corp stake, reports 765,721 shares owned
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 765,721 shares of Pulmonx Corp (LUNG) common stock, which represents 1.8% of the class. BlackRock holds sole voting and sole dispositive power over all these shares, with no shared power. The filing notes that beneficiaries with rights to dividends or sale proceeds are various clients, none of whom hold more than five percent of Pulmonx's outstanding common shares.
Pulmonx Corp. Revenue Breakdown – LSX:A2P1AF
Pulmonx Corp. (LSX:A2P1AF) generated €77.05 million in revenue last year, primarily from its Interventional Pulmonology segment. The United States was the largest contributor to revenue, accounting for €48.55 million in the past year. This report provides a breakdown of the company's financial performance by segment and region.
Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference
Pulmonx Corporation, a leader in minimally invasive treatments for severe lung disease, announced its participation in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference. The event is scheduled for Tuesday, August 11, 2026, at 1:00 PM PT / 4:00 PM ET. A live and archived webcast will be available on the Investors section of the Pulmonx website.
Pulmonx's Aug. 11 Boston fireside chat will be webcast live
Pulmonx (Nasdaq: LUNG) announced it will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, 2026, at 1:00 PM PT / 4:00 PM ET. A live and archived webcast of the event will be accessible through the Investors section of the company's website. Pulmonx is a global leader in minimally invasive treatments for severe lung disease.
Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference
Pulmonx Corporation will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026. The event, taking place in Boston, will also be accessible via a live and archived webcast on the "Investors" section of the company's website. Pulmonx is a global leader in minimally invasive treatments for severe lung disease, known for its Zephyr Endobronchial Valve and other related technologies.
LUNG|Pulmonx Corp|Price:1.225|Chg%:+0.055
This article from TradingKey provides a comprehensive stock analysis of Pulmonx Corp (LUNG), highlighting its relatively healthy fundamentals, significant growth potential, and "fairly valued" status within the Healthcare Equipment & Supplies industry. It notes high institutional ownership and recent "Buy" ratings from analysts with a target price indicating substantial upside. The analysis also details the company's products for COPD treatment and outlines its strengths, risks, and various scoring methodologies used by TradingKey.
Pulmonx Corp (LUNG) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Pulmonx Corp (LUNG), listing its major shareholders and their proportions, as well as categorizing shareholder types. It also provides institutional shareholding data over several quarters and recent shareholder activity. Additionally, the article lists related ETFs that include Pulmonx Corp.
Pulmonx Corp expected to post a loss of 28 cents a share - Earnings Preview
Pulmonx Corp (NASDAQ: LUNG) is anticipated to report a loss of 28 cents per share in its upcoming earnings announcement. This information, provided by Refinitiv, suggests the company is facing an expected negative financial outcome for the period.
Pulmonx Market Sentiment
This article analyzes the market sentiment for Pulmonx (LUNG) based on analyst consensus, short interest, options flow, and insider activity. It highlights a "Buy" consensus from 9 analysts with an average price target of $8, a 3.2% short float, and no recent insider activity. The article also provides a detailed table of recent analyst actions, including ratings, price target changes, and actions by various firms.
Pulmonx Corp. Revenue Breakdown – MUN:4NI
This article provides a revenue breakdown for Pulmonx Corp. (MUN:4NI), showing that its top-performing segment, Interventional Pulmonology, generated €77.05 million last year, down from €80.94 million in the prior year. The United States was the greatest contributor, accounting for €48.55 million, a decrease from the previous year's €54.54 million.
Pulmonx Corp (LUNG) Cash Flow
This article provides a detailed cash flow statement for Pulmonx Corp (LUNG), including operating, investing, and financing cash flows presented quarterly and annually. It outlines key financial metrics and offers definitions for different types of cash flow, along with Pulmonx Corp's specific figures for recent periods. The data helps evaluate the company's financial health, investment activities, and funding strategies.
Pulmonx Corp (LUNG) Financial Health: Profitability & Balance Sheet Analysis
The article provides a financial health analysis of Pulmonx Corp (LUNG), noting its current financial score of 6.77, ranking 133rd in the Healthcare Equipment & Supplies industry. It highlights a stable financial status but low operating efficiency, with recent quarterly revenue decreasing by 8.66% year-over-year and net profit decreasing by 5.50% year-over-year. The analysis covers aspects like financial health, quality of earnings, operational efficiency, growth potential, and shareholder returns, though some detailed data points are noted as not disclosed by the company.
LUNG|Pulmonx Corp|Price:1.225|Chg%:+0.055
This article provides a detailed overview of Pulmonx Corp (LUNG), a commercial-stage medical technology company specializing in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). It highlights the company's key products, including the Zephyr Endobronchial Valve and Chartis Pulmonary Assessment System, and lists its executive team and top shareholders. The financial data shows a market cap of $51.74 million and recent stock performance.
Pulmonx Corp (LUNG) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Pulmonx Corp (LUNG) focusing on its dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years, indicating no recent payouts. The article includes current stock pricing and market capitalization information for Pulmonx Corp.
Pulmonx Corp (LUNG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Pulmonx Corp (LUNG), focusing on its regional revenue contributions. As of the specified date, the company has not yet disclosed detailed data for business segments or specific quarterly financial years. The primary revenue source is the United States, followed by Europe, Middle-East and Africa ("EMEA"), and Asia Pacific.
TradingKey
This article provides a detailed quarterly and annual income statement for Pulmonx Corp (LUNG), offering financial insights into its revenue, operating expenses, and net income. It also includes frequently asked questions about interpreting income statements and key metrics for analyzing LUNG stock. The data covers several fiscal years and quarters, highlighting year-over-year changes in various financial figures.
Pulmonx Corp (LUNG) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Pulmonx Corp (LUNG), noting its current valuation score of 7.71, which ranks 138 out of 200 in the Healthcare Equipment & Supplies industry. The company's P/E ratio is reported as -0.91, and other key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed. The data was last updated on July 24, 2026.
LUNG|Pulmonx Corp|Price:1.220|Chg%:+0.010
Pulmonx Corp (LUNG) closed at 1.170 USD, down 4.10%. The company, a commercial-stage medical technology firm specializing in COPD treatments, shows strong fundamentals and significant growth potential despite a recent weak stock market performance. Analysts rate it a "Buy" with a target price of 3.40, indicating a 178.69% upside.
Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026
Pulmonx Corporation announced it will release its second-quarter 2026 financial results on Wednesday, July 29, 2026, after the close of trading. The company will host a conference call to discuss these results at 1:30 p.m. PT / 4:30 p.m. ET, with a webcast available on its investor relations website. Pulmonx is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD).
Pulmonx Sets July 29 Webcast to Discuss Second-Quarter Results
Pulmonx (Nasdaq: LUNG) announced it will release its second-quarter 2026 financial results after market close on Wednesday, July 29, 2026. The company will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results, which will be accessible via their investor relations website. This announcement notes a mixed historical market reaction to similar notices, with an average stock move of 1.66%.
Pulmonx (NASDAQ:LUNG) Sparks Fresh Penny Stock Buzz
Pulmonx (NASDAQ:LUNG) is attracting attention as a penny stock due to its focus on severe emphysema treatment. The company's key products, the Zephyr Endobronchial Valve and the Chartis system, are highlighted for their role in improving lung function in affected patients. This renewed interest is driven by the strength of the healthcare sector and Pulmonx's innovative medical devices.
Enterprise value to EBIT forward of Pulmonx Corporation – NASDAQ:LUNG
This article briefly highlights the enterprise value to EBIT forward for Pulmonx Corporation (NASDAQ:LUNG). It indicates that the market is currently closed with no trades recorded. The data is provided by ICE Data Services and FactSet, with SEC filings from Quartr.
Pulmonx Corp highlights lung device strategy as a specialized medtech player
Pulmonx Corp positions itself as a specialized medical technology company focusing on minimally invasive devices for severe emphysema and chronic respiratory conditions. Its business model centers on bronchoscopic procedures, generating revenue from implantable devices and associated delivery systems used by specialist physicians. The company's strategy emphasizes regulatory clearances, reimbursement, and clinical evidence to drive adoption and long-term growth in the respiratory care market.
Enterprise value to EBITDA forward of Pulmonx Corp. – LSX:A2P1AF
This page from TradingView provides financial information for Pulmonx Corp. under the ticker LSX:A2P1AF. It focuses on the enterprise value to EBITDA forward metric, but the actual data values are not visible in the provided content. The page also includes various navigation and informational links related to trading and financial analysis tools.
Enterprise value to EBIT forward of Pulmonx Corp. – LSX:A2P1AF
This article focuses on the "Enterprise value to EBIT forward" metric for Pulmonx Corp. (LSX:A2P1AF). It appears to be a financial data snippet from TradingView, providing an overview of a specific valuation ratio for the company's stock. The content points to financial data available on the platform, indicating market and company-specific information.
Price to earnings forward of Pulmonx Corp. – LSX:A2P1AF
This article provides the "Price to earnings forward" valuation metric for Pulmonx Corp. (LSX:A2P1AF). It indicates the value and change of this financial data point over a period. The information is presented within the context of TradingView's platform, which offers various financial tools and market data services.
Price to earnings forward of Pulmonx Corp. – DUS:4NI
This article provides the "Price to earnings forward" data for Pulmonx Corp. (DUS:4NI) on the TradingView platform. It details the company's financial information, presented within the context of the Düsseldorf Stock Exchange. The content is primarily a data page on a financial platform rather than an analytical article.
Price to sales forward of Pulmonx Corp. – DUS:4NI
This page from TradingView provides financial information for Pulmonx Corp. (4NI) listed on the Dusseldorf Stock Exchange, specifically focusing on its forward price-to-sales ratio. The article includes standard market data and copyright information, indicating that the market for this stock is currently closed with no recent trades.
Pulmonx Corp highlights its respiratory device portfolio as investors assess long-term growth prospects
Pulmonx Corp (PULM) focuses on developing minimally invasive medical devices for severe emphysema and other chronic obstructive pulmonary diseases, targeting a significant unmet medical need. The company's business model involves selling specialized devices to healthcare providers and supporting their usage with training. Investors evaluate Pulmonx's prospects based on its ability to expand device adoption, enter new markets, and maintain regulatory and reimbursement support.
Pulmonx Corp. Actuals & Estimates (NASDAQ:LUNG)
This article provides financial actuals and estimates for Pulmonx Corporation (NASDAQ: LUNG), including its current stock price, historical performance, analyst forecasts, and company financials. It details the company's market capitalization, last quarter's earnings and revenue, and upcoming earnings report date. The company does not pay dividends and has 296 employees.
Pulmonx Corp (LUNG) Financial Health: Profitability & Balance Sheet Analysis
Pulmonx Corp (LUNG) has a stable financial status but low operating efficiency, ranking 142 out of 204 in the Healthcare Equipment & Supplies industry with a financial score of 6.69. The company's latest quarterly revenue decreased by 8.66% year-over-year to $20.59 million, and its net profit saw a 5.50% year-over-year decline. Key financial metrics related to cash, assets, revenue, and profit are mentioned, though specific details beyond quarterly figures are noted as not yet disclosed.
Pulmonx Corp (LUNG) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Pulmonx Corp (LUNG), highlighting its price momentum score of 5.32 within the Healthcare Equipment & Supplies industry. It details the stock's current trading range between a resistance level of $1.59 and a support level of $1.09, suggesting suitability for range-bound swing trading. The analysis also includes aggregated technical indicators, predominantly signaling a "Sell" based on moving averages.
Pulmonx Corp (LUNG) Institutional Confidence
Pulmonx Corp (LUNG) has an institutional shareholding score of 7.00, placing it 79th out of 204 in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion increased by 10.02% quarter-over-quarter to 87.40%. James Simons is noted as the largest institutional shareholder, though other significant holders like PRIMECAP Management Company and Morgan Stanley & Co. LLC are also listed with their respective shareholdings and changes.
Pulmonx Corp (LUNG) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Pulmonx Corp (LUNG), highlighting its current earnings forecast score, average price target of $4.50, and analyst ratings. Based on 5 analysts, the stock has a "Buy" trend. The article also includes expected revenue and EPS for upcoming quarters and compares LUNG to its peers in the Healthcare Equipment & Supplies industry.
Pulmonx Corp (LUNG) Valuation: PE, PB & Fair Value Analysis
The article provides a valuation analysis for Pulmonx Corp (LUNG), noting its current valuation score is 7.71, ranking 137 out of 204 in the Healthcare Equipment & Supplies industry. It highlights the company's P/E ratio of -0.97, which represents a decrease from its recent high and an increase from its recent low. The analysis indicates that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Pulmonx Corp (LUNG) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Pulmonx Corp's (LUNG) dividend and stock split history, noting that no dividend data or stock split data is available. It shows the current stock price, market cap, and links to various company and market analysis sections on the TradingKey platform.
Pulmonx Corp (LUNG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Pulmonx Corp (LUNG), detailing its revenue by geographical region for the fiscal year 2023. The United States contributed the largest portion of revenue at 63.01% ($57.02 million), followed by Europe, Middle-East and Africa ("EMEA") and Asia Pacific. The company has not yet disclosed relevant data for business segment revenue.
[Form 4] Pulmonx Corp Insider Trading Activity
Pulmonx Corp director Thomas William Burns has been granted 40,000 Restricted Stock Units (RSUs) as compensation, not through a market purchase. These RSUs, valued at $0.0000 per share, will vest on the earlier of one year from the June 5, 2026 grant date or the date of the Annual Meeting of Stockholders for the subsequent year. Following this grant, Burns directly holds 113,399 shares of Pulmonx common stock.
Pulmonx (LUNG) director receives 40,000-share RSU stock grant
Pulmonx Corp director Dana G. Mead Jr. was granted 40,000 Restricted Stock Units (RSUs) which are payable in common stock. This is an equity compensation award, not an open-market purchase, with a grant price of $0.00 per share. These RSUs will vest on the earlier of June 5, 2026, or the company’s next annual stockholder meeting, increasing Mead's direct holdings to 139,714 Pulmonx shares, plus 4,076 shares held indirectly through The Mead Family Trust.
